Physician profile
John S Link
NPI 1245281211
$2,869.74
in general payments reported to CMS, 2019-2025
27 companies · $68.92 in 2025
The $68.92 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,438 · 2020: $545 · 2021: $508 · 2022: $238 · 2023: $56.06 · 2024: $16.07 · 2025: $68.92.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $141.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $141.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $365.80 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $316.73 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $313.61 | 2019-2023 | |
| Genentech USA, INC. | $202.76 | 2019-2021 | |
| Foundation Medicine, INC. | $170.48 | 2019-2021 | |
| Pfizer INC. | $144.07 | 2019-2021 | |
| Eisai INC. | $142.92 | 2019-2021 | |
| Janssen Scientific Affairs, LLC | $140.53 | 2022 | |
| Merck Sharp & Dohme LLC | $115.35 | 2019-2021 | |
| Celgene Corporation | $110.38 | 2019 | |
| Puma Biotechnology, INC. | $101.48 | 2019-2022 | |
| Seagen INC. | $101.09 | 2020-2021 | |
| Gilead Sciences, INC. | $98.30 | 2021-2025 | Trodelvy |
| Tersera Therapeutics LLC | $79.87 | 2019-2021 | |
| Mylan Institutional INC. | $77.45 | 2019-2021 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $69.81 | 2019 | |
| Emd Serono, INC. | $67.49 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $44.30 | 2019-2021 | |
| Boston Scientific Corporation | $42.05 | 2025 | Wavewriter Alpha Prime 16 |
| Heron Therapeutics, INC. | $35.01 | 2020-2021 | |
| Ge Healthcare | $30.45 | 2022 | |
| Mayne Pharma Commercial LLC | $25.74 | 2022 | |
| Incyte Corporation | $21.42 | 2021 | |
| Array Biopharma INC | $20.56 | 2022 | |
| Kyowa Kirin, INC. | $17.52 | 2019 | |
| Helsinn Therapeutics (U.S.), INC. | $14.57 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Link listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.